Pds Biotechnology Corp (PDSB) Stock Price, Quote & News

Company Profile

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies. The company's lead product candidate is Versamune HPV, which is in phase II clinical trial for the treatment of head and neck, cervical, anal, vaginal, vulvar, and penile cancers. It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy utilizing tumor-associated and immunologically active T c...

Industry: Biotechnology

Sector: Healthcare

Phone: 800 208 3343

Website: www.pdsbiotech.com

Address:

303A College Road East, Princeton, United States

dvice2 Jul. 31 at 10:43 PM

$PDSB ill buy again under $1 but thats about it. doesnt matter what they have going - mgmt has failed shareholders by not securing meaningful capital. what a shame. things can change but nothing looks good outside of data and being in a ph3 (that they cant fund). glt anyone still holding, we need it.

2 · Reply

EddieH2020 Jul. 31 at 8:18 PM

$PDSB I emailed IR 13 days ago and have not heard anything. They honestly don’t care about shareholders.

0 · Reply

wyoming2020 Jul. 31 at 12:43 PM

$PDSB is time for one more raise for $5-$7M? With about $40M in cash that would get the company close to competing phase 3 and phase 2 of MUCI-1. It's getting tight now but maybe better to do than not do. How many shares does NetScientific still hold? I'll see if i can find but they were once a big holder if I remember right. Merck Gaa holds quite a few shares I believe (I'll check) in the Versamune acquisition. Exciting as the company nearly there for Phase 3 but the clock is running out. Reminds me of the Bear restaurant show!

3 · Reply

Ontherag Jul. 30 at 9:03 PM

$PDSB At least we got the C-suite locked in

0 · Reply

bmess Jul. 30 at 5:47 PM

$PDSB https://clinicaltrials.gov/study/NCT07090174?term=Versamune&rank=1

1 · Reply

bmess Jul. 30 at 5:47 PM

$PDSB https://clinicaltrials.gov/study/NCT06790966?term=Versamune&rank=2 added a new location

0 · Reply

Mr_Charlie Jul. 30 at 5:29 PM

$PDSB rubbish

0 · Reply

EddieH2020 Jul. 30 at 3:59 PM

$PDSB If your PDS average is above $2.50 you might never profit at this point tbh

3 · Reply

mikeywo Jul. 30 at 2:52 PM

$PDSB Frank is hoping for sub1$ so he can have an excuse to RS and start the dilution all over again.

0 · Reply

dvice2 Jul. 30 at 2:31 PM

$PDSB 13

1 · Reply

PDS Biotech Announces Colorectal Cancer Cohort of Phase 2 Clinical Trial with PDS01ADC Met Criteria for Expansion to Stage 2 Following Positive Stage 1 Results

Jun 9, 2025, 8:00 AM EDT - 7 weeks ago

PDS Biotech to Host Key Opinion Leader Event to Discuss Versamune® HPV for the Treatment of HPV16+ HNSCC

Jun 2, 2025, 8:00 AM EDT - 2 months ago

PDS Biotech Unveils Updated Positive Data From VERSATILE-002 Trial and Additional Trials Evaluating Versamune® HPV to Treat Head and Neck Cancers at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

May 22, 2025, 5:26 PM EDT - 2 months ago

PDS Biotech Announces Positive Extended Follow-Up Data for VERSATILE-002 and Additional Trials Evaluating Versamune® HPV to be Presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

May 20, 2025, 8:00 AM EDT - 2 months ago

PDS Biotech to Participate at the A.G.P. Virtual Annual Healthcare Company Showcase

May 14, 2025, 12:57 PM EDT - 2 months ago

PDS Biotechnology Corporation (PDSB) Q1 2025 Earnings Call Transcript

May 14, 2025, 7:30 AM EDT - 2 months ago

PDS Biotech Reports First Quarter 2025 Financial Results and Provides Clinical Programs and Corporate Update

May 9, 2025, 4:05 PM EDT - 2 months ago

PDS Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

May 8, 2025, 8:00 AM EDT - 3 months ago

PDS Biotech Announces Additional Details on Two Preclinical Universal Influenza Presentations at IMMUNOLOGY2025™ Annual Meeting

May 7, 2025, 8:00 AM EDT - 3 months ago

PDS Biotech Announces Conference Call and Webcast for First Quarter 2025 Financial Results

Apr 23, 2025, 10:16 AM EDT - 3 months ago

PDS Biotech Announces Multiple Abstracts Selected for Presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 16, 2025, 8:00 AM EDT - 3 months ago

PDS Biotech Announces Preclinical Influenza Data to be Presented in Symposium at IMMUNOLOGY2025™ Annual Meeting

Apr 8, 2025, 8:00 AM EDT - 4 months ago

PDS Biotech Announces PDS01ADC Clinical Data to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2025

Mar 27, 2025, 10:35 AM EDT - 4 months ago

PDS Biotechnology Corporation (PDSB) Q4 2024 Earnings Call Transcript

Mar 27, 2025, 7:30 AM EDT - 4 months ago

PDS Biotech Reports Full Year 2024 Financial Results and Provides Clinical Programs Update

Mar 25, 2025, 8:00 AM EDT - 4 months ago

PDS Biotech Leadership to Present at 2025 CAGLA NeauxCancer Conference

Mar 18, 2025, 8:00 AM EDT - 4 months ago

PDS Biotech Announces Conference Call and Webcast for Full Year 2024 Financial Results

Mar 13, 2025, 8:00 AM EDT - 5 months ago

PDS Biotech Announces FDA Clearance of IND Application for Combination of Versamune® MUC1 and PDS01ADC to Treat Metastatic Colorectal Cancer

Mar 11, 2025, 8:00 AM EDT - 5 months ago

PDS Biotech Leadership to Participate in March Conferences

Mar 7, 2025, 8:45 AM EST - 5 months ago

PDS Biotech Initiates VERSATILE-003 Phase 3 Clinical Trial Evaluating Versamune® HPV in HPV16-Positive Head and Neck Cancer

Feb 27, 2025, 8:00 AM EST - 5 months ago

PDS Biotech Announces up to $22 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Feb 26, 2025, 8:00 AM EST - 5 months ago

PDS Biotech Announces Positive Clinical Data Demonstrating Compelling Survival and Clinical Responses in Recurrent/Metastatic HPV-Associated Cancers Published in JAMA Oncology

Feb 24, 2025, 8:00 AM EST - 5 months ago

PDS Biotech Announces Circulating Tumor DNA Results for Versamune® HPV in IMMUNOCERV Trial Published in Clinical Cancer Research

Feb 20, 2025, 8:00 AM EST - 5 months ago

PDS Biotech to Participate at B. Riley Securities Precision Oncology & Radiopharma Conference 2025

Dec 3, 2024, 8:00 AM EST - 8 months ago

PDS Biotech to Host Key Opinion Leader Event on December 17 at 12 p.m. ET

Nov 14, 2024, 11:18 AM EST - 9 months ago

PDS Biotechnology Corporation (PDSB) Q3 2024 Earnings Call Transcript

Nov 6, 2024, 8:00 AM EST - 9 months ago

PDS Biotech to Announce Third Quarter Financial Results on November 14, 2024 at 8:30 a.m. Eastern Time

Oct 2, 2024, 8:00 AM EDT - 10 months ago

PDS Biotech Announces 36-Month Overall Survival Rate of 84.4% in Locally Advanced Cervical Cancer Patients Treated with Versamune® HPV and Chemoradiation

Sep 23, 2024, 10:39 AM EDT - 11 months ago

PDS Biotechnology: Continuing The Holding Pattern

Sep 9, 2024, 8:00 AM EDT - 11 months ago

PDS Biotech to Present Updated VERSATILE-002 Data at ESMO Congress 2024

Sep 3, 2024, 8:00 AM EDT - 11 months ago

PDS Biotech to Present at H.C. Wainwright 26th Annual Global Investment Conference

Aug 7, 2024, 8:00 AM EDT - 1 year ago

PDS Biotech to Announce Second Quarter Financial Results on August 13, 2024

Aug 2, 2024, 9:12 AM EDT - 1 year ago

PDS Biotechnology Corporation (PDSB) Clinical Program Update Conference Call (Transcript)

Aug 1, 2024, 7:45 AM EDT - 1 year ago

PDS Biotech Aligns with FDA on Phase 3 Trial in HPV16-Positive First-Line Recurrent or Metastatic Head and Neck Cancer

Jul 31, 2024, 4:01 PM EDT - 1 year ago

PDS Biotech to Host Clinical Program Update Conference Call on August 1, 2024, at 8 a.m. Eastern Time

May 15, 2024, 8:00 AM EDT - 1 year ago

PDS Biotech Provides Business Update and Reports First Quarter 2024 Financial Results

May 9, 2024, 5:46 PM EDT - 1 year ago

PDS Biotech VERSATILE-002 Phase 2 Clinical Trial Meets Primary Study Endpoints in First Line Recurrent/Metastatic HPV16-Positive Head and Neck Cancer

May 7, 2024, 8:00 AM EDT - 1 year ago

PDS Biotech to Announce First Quarter 2024 Financial Results on May 15, 2024

May 3, 2024, 8:00 AM EDT - 1 year ago

PDS Biotechnology Announces Details of Virtual KOL Event

May 2, 2024, 8:00 AM EDT - 1 year ago

PDS Biotech Appoints Stephan Toutain as Chief Operating Officer

Apr 23, 2024, 8:00 AM EDT - 1 year ago

PDS Biotech to Host Key Opinion Leader Event to Discuss Positive, Updated Data from Phase 2 VERSATILE-002 Clinical Trial with Versamune® HPV in Combination with KEYTRUDA® in Recurrent or Metastatic Head and Neck Cancer

Mar 27, 2024, 12:17 PM EDT - 1 year ago

PDS Biotechnology Corporation (PDSB) Q4 2023 Earnings Call Transcript

Mar 27, 2024, 7:30 AM EDT - 1 year ago

PDS Biotech Announces Clinical Strategy Update and Reports Full Year 2023 Financial Results

Mar 20, 2024, 8:00 AM EDT - 1 year ago

PDS Biotechnology Announces Conference Call and Webcast for Business Update and Full Year 2023 Financial Results

Mar 13, 2024, 8:00 AM EDT - 1 year ago

PDS Biotech Announces Publication of Preclinical Research and Grant of U.S. Composition of Matter Patent for Infectimune®

Jan 26, 2024, 6:59 PM EST - 1 year ago

PDS Biotechnology: Advancement Of PDS0101 Continues With Expansion Data

Jan 22, 2024, 4:45 PM EST - 1 year ago

PDS Biotech Announces Retirement of Lauren V. Wood, M.D.

Jan 16, 2024, 8:00 AM EST - 1 year ago

PDS Biotech to Participate at B. Riley Securities 4th Annual Oncology Conference

Nov 28, 2023, 7:30 AM EST - 1 year ago

PDS Biotech Appoints Lars Boesgaard as Chief Financial Officer

Nov 14, 2023, 12:17 PM EST - 1 year ago

PDS Biotechnology Corporation (PDSB) Q3 2023 Earnings Call Transcript

dvice2 Jul. 31 at 10:43 PM

2 · Reply

EddieH2020 Jul. 31 at 8:18 PM

$PDSB I emailed IR 13 days ago and have not heard anything. They honestly don’t care about shareholders.

0 · Reply

wyoming2020 Jul. 31 at 12:43 PM

3 · Reply

Ontherag Jul. 30 at 9:03 PM

$PDSB At least we got the C-suite locked in

0 · Reply

bmess Jul. 30 at 5:47 PM

$PDSB https://clinicaltrials.gov/study/NCT07090174?term=Versamune&rank=1

1 · Reply

bmess Jul. 30 at 5:47 PM

$PDSB https://clinicaltrials.gov/study/NCT06790966?term=Versamune&rank=2 added a new location

0 · Reply

Mr_Charlie Jul. 30 at 5:29 PM

$PDSB rubbish

0 · Reply

EddieH2020 Jul. 30 at 3:59 PM

$PDSB If your PDS average is above $2.50 you might never profit at this point tbh

3 · Reply

mikeywo Jul. 30 at 2:52 PM

$PDSB Frank is hoping for sub1$ so he can have an excuse to RS and start the dilution all over again.

0 · Reply

dvice2 Jul. 30 at 2:31 PM

$PDSB 13

1 · Reply

PSM_EmpowerTrading Jul. 30 at 1:10 PM

🌞🌞 watchlist part 3 ✅️ $CRDF low 2.20 support, if above 2.65, have potential to 3/3.30, Positive Data from Ongoing Randomized Phase 2 First-line RAS-mutated mCRC Clinical Trial (CRDF-004) 🚀🚀 recent swing runner $HWH up 135% from below 1.35 alert posted during swing accumulation phase 🚨🚨 The above tickers are not ideal for swing accumulation at current price 🎯 🎯 Ideal long stop loss if current support 🚫🚫 Avoid chasing long into strength near resistance ✅️✅️ $LMFA $PDSB still in swing accumulation phase 🎯🎯 Goal is GR🤑🤑N not GR🥵🥵D

1 · Reply

Ontherag Jul. 30 at 11:50 AM

$PDSB https://endpoints.news/vinay-prasad-out-at-fda-after-agency-backtracks-on-sarepta-decision/ Thankful for Vinay speaking out during covid, but he is not the right person at the FDA. I think this is good for us.

0 · Reply

PSM_EmpowerTrading Jul. 30 at 2:54 AM

🌅🌅 watchlist part 2 ✅️ $ACRS mid 1.60 support, if above 2, have potential to 2.30/2.50, meets primary and secondary endpoints for ATI-2138 trial, phase 2 in patients with moderate to severe atopic dermatitis ✅️ $CRDF low 2.20 support, if above 2.65, have potential to 3/3.30, Positive Data from Ongoing Randomized Phase 2 First-line RAS-mutated mCRC Clinical Trial (CRDF-004) 🤑🤑🚀🚀 recent swing runner $HWH up 135% from below 1.35 alert posted during swing accumulation phase 🚨🚨 The above tickers are not ideal for swing accumulation at current price 🎯 🎯 Ideal long stop loss if current support 🚫🚫 Avoid chasing long into strength near resistance ✅️✅️ $LMFA $PDSB still in swing accumulation phase 🎯🎯 Goal is GR🤑🤑N not GR🥵🥵D

1 · Reply

i81b4u Jul. 29 at 4:22 PM

$PDSB Aot of buying going. But as of now the ask isn't moving. Fing MM

0 · Reply

Test2025 Jul. 29 at 3:40 PM

$PDSB everyone is gone

1 · Reply

dvice2 Jul. 29 at 2:24 PM

$PDSB new study involving PDS0101 This study is testing the immunotherapeutic agent, PDS0101, in adults living with HIV who are also infected with human papillomavirus (HPV) type 16. The purpose of the study is to learn whether PDS0101 is safe and whether it can help the body's immune system respond to HPV 16. Researchers will enroll 27 adults between the ages of 25 and 65 who have been receiving antiretroviral therapy (ART) for at least 12 months, have a CD4 cell count of at least 200 cells/mm³, and have an HIV viral load below 200 copies/mL. All participants must have HPV 16 detected in the cervix, vagina, or anus. Some participants will have high-grade squamous intraepithelial lesions (HSIL), a condition that can lead to cancer. At least 10 participants will have cervical HSIL, and at least 10 will have anal HSIL. Participants with both cervical and anal HSIL will count in both groups. Others may have HPV 16 without HSIL. https://clinicaltrials.gov/study/NCT07090174?term=Pds0101&rank=1

2 · Reply

Stockman824 Jul. 28 at 12:32 PM

$PDSB they at least owe ALL of us NON DILUTIVE financing at the worst and at best a huge partnership with a large upfront cash payment!!

1 · Reply

EddieH2020 Jul. 27 at 6:30 PM

$PDSB Lowered my PDS average to $3.98. Can lower it below $2 but I’m choosing instead to buy into MREO for YE News. 👌

1 · Reply

FesertBoy Jul. 26 at 6:58 PM

$PDSB lmao bros been on a roll lately 😂. Fireside chat this week is hard work

0 · Reply

i81b4u Jul. 26 at 6:11 PM

$PDSB Lot of options given out. But at a higher price then it is now. Lets get that news we all been waiting for!

1 · Reply

Ontherag Jul. 26 at 4:31 PM

$PDSB Time for Frank to drop the news of partnership and reward his team for the great work they have been doing

0 · Reply

Ontherag Jul. 25 at 11:26 PM

$PDSB A Form-4 just came out, Frank just gave everyone a ton of options at 1.79, I hope they earned it.

2 · Reply

Market Cap	52.11M
Revenue (ttm)	0.00
Net Income (ttm)	-37.61M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.28

Volume	227,600
Avg Vol	663,760
Day's Range	N/A - N/A
Shares Out	45.71M
Stochastic %K	11%
Beta	1.21
Analysts	Strong Sell
Price Target	$7.50